Monopar Therapeutics’ (MNPR) Buy Rating Reaffirmed at BTIG Research

BTIG Research reiterated their buy rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research report report published on Monday morning,Benzinga reports. The firm currently has a $104.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the stock. Chardan Capital reissued a “buy” rating and issued a $100.00 target price on shares of Monopar Therapeutics in a research report on Thursday, January 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, January 22nd. Barclays set a $125.00 target price on Monopar Therapeutics and gave the stock an “overweight” rating in a report on Monday, October 13th. Morgan Stanley assumed coverage on Monopar Therapeutics in a research report on Friday, January 9th. They issued an “overweight” rating and a $115.00 target price for the company. Finally, Jones Trading raised Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $107.00.

Monopar Therapeutics Price Performance

Shares of Monopar Therapeutics stock opened at $65.48 on Monday. Monopar Therapeutics has a 1-year low of $26.06 and a 1-year high of $105.00. The company has a market capitalization of $437.60 million, a PE ratio of -19.03 and a beta of 1.46. The business has a 50-day moving average of $71.39 and a 200-day moving average of $65.92.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). On average, equities analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Quan Anh Vu purchased 1,500 shares of the stock in a transaction dated Friday, December 26th. The stock was acquired at an average price of $69.95 per share, for a total transaction of $104,925.00. Following the completion of the transaction, the chief financial officer owned 1,500 shares of the company’s stock, valued at approximately $104,925. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

A number of hedge funds have recently made changes to their positions in MNPR. Russell Investments Group Ltd. acquired a new stake in Monopar Therapeutics in the 3rd quarter valued at approximately $28,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Monopar Therapeutics during the 2nd quarter worth $34,000. BNP Paribas Financial Markets grew its stake in shares of Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares in the last quarter. AlphaQuest LLC grew its stake in shares of Monopar Therapeutics by 46.8% in the second quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock worth $64,000 after purchasing an additional 569 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares during the period. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.